AbbVie Inc. ABBV stock is up slightly on Friday on new data presented at the European Hematology Association (EHA) 2026 ...
New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...
For years, treatment of older patients with acute myeloid leukemia—an aggressive cancer of the blood and bone marrow—has ...
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an ...
AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, ...
Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective ...
The pretreatment evaluation of patient-reported, health-related quality of life provides valuable prognostic information on ...
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML. Treating acute leukemias, acute lymphoblastic ...
In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results